Sulfoglycolipids as candidate antiangiogenic radiosensitizers

Anti-Cancer Drugs

Volumn 18, Issue 1, 2007, Pages 1-5

  Miura, Masahiko ^a   Sakimoto, Ippei ^a   Ohta, Keisuke ^a,b   Sugawara, Fumio ^b   Sakaguchi, Kengo ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Angiogenesis; Antiangiogenesis; Radiation; Radiosensitizer; Vascular endothelial cells

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; RADIOSENSITIZING AGENT; SULFATIDE; SULFOQUINOVOSYLACYLGLYCEROL;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL AGING; CLINICAL PRACTICE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; GLYCOLIPIDS; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845608378     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000236318.81327.69     Document Type: Review

References (30)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739.
3. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97:1093-1107.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
5. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Noses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
6. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
7. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-407.
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II trial, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
9. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
10. Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU54 16 in patients with solid tumors. J Clin Oncol 2003; 20:1657-1667.
11. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-291.
12. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-5570.
13. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radio sensitizing endothelial cells. Int J Cancer 2005; 115:312-319.
14. Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, Balligand JL, Feron O. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 2003; 63:1012-1019.
15. 165. Int J Radiat Oncol Biol Phys 2001; 50:213-220.
16. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14:198-206.
17. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001; 61:5491-5498.
18. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997; 37:1107-1113.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
20. Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005; 21:761-767.
21. Phillips TL. Clinical and experimental alterations in the radiation therapeutic ratio caused by cytotoxic chemotherapy. In: Meyers RE, Withers HR, editors. Radiation biology in cancer research. New York: Raven Press; 1980. pp. 567-588.
22. Sahara H, Ishikawa M, Takahashi N, Ohtani S, Sato N, Gasa S, et al. In vivo anti-tumour effect of 3″-sulphonoquinovosyl 1′- monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 1997; 75:324-332.
23. Ohta K, Mizushina Y, Hirata N, Takemura M, Sugawara F, Matsukage A, et al. Sulfoquinovosyldiacylglycerol, KM043, a new potent inhibitor of eukaryotic DNA polymerases and HIV-reverse transcriptase type 1 from a marine red alga, Gigartina tenella. Chem Pharm Bull (Tokyo) 1998; 46:684-686.
24. Sahara H, Hanashima S, Yamazaki T, Takahashi S, Sugawara F, Ohtani S, et al. Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin's natural sulfonoquinovosylmonoacylglycerols. Jpn J Cancer Res 2002; 93:85-92.
25. Sakimoto I, Ohta K, Yamazaki T, Ohtani S, Sahara H, Sugawara F, et al. α-Sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 2006; 66:2287-2295.
26. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155-1159.
27. Hanashima S, Mizushina Y, Ohta K, Yamazaki T, Sugawara F, Sakaguchi K. Structure-activity relationship of a novel group of mammalian DNA polymerase inhibitors, synthetic sulfoquinovosylacylglycerols. Jpn J Cancer Res 2000; 91:1073-1083.
28. Ohta K, Hanashima S, Mizushina Y, Yamazaki T, Saneyoshi M, Sugawara F, et al. Studies on a novel DNA polymerase inhibitor group, synthetic sulfoquinovosylacylglycerols: inhibitory action on cell proliferation. Mutat Res 2000; 467:139-152.
29. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001; 20:3266-3280.
30. Matsumoto K, Takenouchi M, Ohta K, Ohta Y, Imura T, Oshige M, et al. Design of vesicles of 1,2-di-O-acyl-3-O-(beta-D-sulfoquinovosyl)-glyceride bearing two stearic acids (beta-SQDG-C18), a novel immunosuppressive drug. Biochem Pharmacol 2004; 68:2379-2386.